Investigating how oxidative stress affects heart damage from doxorubicin in different racial groups
Official title: Role of oxidative stress in doxorubicin-induced cardiotoxicity racial disparities
Funded at Louisiana State Univ Hsc Shreveport · NIH-10994899 · Data updated 2026-11-12
This study is looking into why African Americans may have more heart problems from the cancer drug doxorubicin than White Americans, by exploring how a specific gene and oxidative stress affect heart cells, using samples from both groups to find out what makes their responses different.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Louisiana State Univ Hsc Shreveport NIH-funded |
| Lab location | 1 site (Shreveport, United States) |
| Project start | February 1, 2018 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $219,000 |
| NIH project number | 5P20GM121307-07 |
| Project ID | NIH-10994899 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include African American and White American individuals who have been treated with doxorubicin or are at risk of receiving this treatment.
✕Less likely to help
Patients who are not receiving doxorubicin or do not have a history of heart issues related to cancer treatment may not benefit from this research.
What this research studies
This research focuses on understanding why African Americans experience higher rates of heart damage from the cancer drug doxorubicin compared to White Americans. It examines the role of oxidative stress and a specific gene, EPHA2.AS1, which may influence how heart cells respond to the drug. By using patient-specific heart cells derived from both African American and White American individuals, the study aims to identify differences in cellular responses and potential genetic factors that contribute to this disparity. The research employs advanced techniques to measure oxidative stress and its effects on heart function.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for preventing heart damage in patients receiving doxorubicin, particularly among African Americans.
How similar studies have gone: Previous research has indicated that oxidative stress plays a significant role in drug-induced cardiotoxicity, suggesting that this approach may yield valuable insights.
Where this research is happening
-
Louisiana State Univ Hsc Shreveport
Shreveport, United States Active
Researchers
- Principal investigator: Mohamed, Tarek Magdy — Louisiana State Univ Hsc Shreveport
- Study coordinator: Mohamed, Tarek Magdy
Related research
Other NIH-funded projects on the same topics.
-
Understanding why some patients have heart damage from doxorubicin and how to predict it
This grant looks at why doxorubicin can damage the heart in some patients and how genetic differences, especially related to oxidative stress, might help predict who is at higher risk.
-
Understanding Heart Damage from Doxorubicin Chemotherapy
This research explores why some patients experience heart damage from doxorubicin chemotherapy while others don't, focusing on individual genetic differences.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
-
How vitamin B12 helps the gum-disease bacterium survive
Learning how vitamin B12 helps the bacteria that cause gum disease survive and become more harmful for people with periodontitis.
-
Genetic clues for doxorubicin heart risk using patient-derived heart cells
A research project tests how human heart cells grown from stem cells react to a common chemotherapy to see which genetic differences may raise the risk of heart damage.
-
Targeting STK3 to protect the heart during breast cancer treatment
A new approach tests whether blocking STK3 can protect the heart from chemotherapy damage without reducing its cancer-fighting effect in breast cancer patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.